392.95 -0.08 (-0.02%)
After hours: 4:21PM EST
|Bid||384.00 x 200|
|Ask||400.00 x 500|
|Day's Range||390.31 - 394.29|
|52 Week Range||203.57 - 400.00|
|PE Ratio (TTM)||56.48|
|Earnings Date||Jan 22, 2018 - Jan 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||373.94|
The market is upbeat about Intuitive Surgical's (ISRG) solid procedure performance in Asia, with growth in China, Japan and Korea.
Intuitive Surgical (ISRG) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.
Intuitive Surgical's (ISRG) sales to gain from on da Vinci system and procedural growth in general surgery, oncology, urology and gynecology.
Investors in Intuitive Surgical (ISRG) need to pay close attention to the stock based on moves in the options market lately.
The Zacks Analyst Blog Highlights: Activision, Marriott, Intuitive Surgical, Edison International and TELUS
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding ISRG is favorable, with net inflows of $16.30 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing.
Intuitive Surgical’s Services business accounts for around 17% of the company’s value, according to our estimates. The segment primarily includes full-time support to Intuitive Surgical customers, from installing its surgical systems to
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
Intuitive Surgical‘s stock has jumped more than 2x in the last couple of years, and the year 2017 has been especially strong. While we think that the fundamentals justify the stock surge in large part, the current price level may be unsustainable
Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.
OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and forex woes.
Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Intuitive Surgical, Inc. Here are 5 ETFs with the largest exposure to ISRG-US. Comparing the performance and risk of Intuitive Surgical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)